The effect of citalopram versus a placebo on central auditory processing in the elderly.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000570684

Acronym

citalopram_cap

Enrollment

Registered

2014-05-28

Start date

2015-10-19

Completion date

2016-01-15

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Elderly with 60 years or more, with hearing impairment detected and confirmed by poor performance in Central Auditory Processing tests. 60 Subjects will be divided into two groups and given citalopram 20 mg/day or placebo for 6 months. Hearing evaluation will be performed initially and after 6 months and will include pure-tone audiometry, speech discrimination test (SDT), emittanciometry, hearing handicap inventory for elderly test (HHIE), minimental cognitive test and Central Auditory Processing evaluation.

Interventions

citalopram 20 mg/day, in oral capsule, for 6 months; Medical consultation every 2 months for drug delivery. At same time, the adherence will be evaluated as well as collateral effects or even other clinical benefits from the drug.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

Subjects with hearing threshold from normal to moderate loss and with low performance in central auditory processes tests.

Exclusion criteria

Contraindications for the drug (citalopram).

Outcome results